TWELVE ZERO TWO

Brand Owner Address Description
TWELVEZEROTWO AT LAST SPORTSWEAR, INC. 110 Enterprise Ave South Secaucus NJ 07094 TWELVE ZERO TWO;Bottoms as clothing for Children, Women, Men, and Adults Clothing; Coats for Children, Women, Men, and Adults Clothing; Jackets for Children, Women, Men, and Adults Clothing; Knitwear, namely, Children, Women, Men, and Adults Clothing; Pajamas for Children, Women, Men, and Adults Clothing; Pants for Children, Women, Men, and Adults Clothing; Shirts for Children, Women, Men, and Adults Clothing; Shoes for Children, Women, Men, and Adults Clothing; Shorts for Children, Women, Men, and Adults Clothing; Sweaters for Children, Women, Men, and Adults Clothing; Sweatpants for Children, Women, Men, and Adults Clothing; Sweatshirts for Children, Women, Men, and Adults Clothing; T-shirts for Children, Women, Men, and Adults Clothing; Tops as clothing for Children, Women, Men, and Adults Clothing; Trousers for Children, Women, Men, and Adults Clothing; Woven shirts for Children, Women, Men, and Adults Clothing;
 

Where the owner name is not linked, that owner no longer owns the brand

   
Technical Examples
  1. The present invention is directed to a method to prevent or reduce postoperative corneal subepithelial haze after excimer laser photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK) surgery. According to the method, a therapeutically effective amount of one or more plasminogen activators, most preferably urokinase (uPA), is administered topically to the surface of the affected eye at levels between 0.1 and 2,500 IU/ml, about eight to twelve times on the day of surgery, and four to eight times per day for about the next six to twelve days thereafter. The most preferred therapeutic amount is from about 0.1-1 IU uPA/ml, and also 1-10 IU/ml. Plasminogen activators that can be used in the inventions include urokinase, prourokinase, streptokinase and mutants thereof. The invention also covers topical ophthalmic compositions that include one or more plasminogen activators, most preferably uPA, to prevent or reduce postoperative corneal subepithelial haze.